MA in Journalism from the University of Sunderland, NCTJ accreditation,
Editor of Cannabis Health (2019-2023); Contributor at Forbes (2023-present); Panel Moderator at Cannabis Europa, Product Earth, and Drug Science’s UK Patient Conference (2023); Reporter on women’s health, health technology, biotech, longevity, and neurorehabilitation medicine.
Forbes, Cannabis Health, Business of Cannabis, Drug Science.
Sarah is a highly respected journalist, with over a decade of experience in publishing and communications, the last four of which have been in specialist healthcare sectors. She is one of the few UK journalists specialising in cannabis-related health and policy, with work that spans the fields of science, medicine, wellness and drug policy. As the former editor of Cannabis Health, an industry-leading and award-winning title covering the potential of cannabis for health and wellbeing, she has been at the forefront of the UK medical cannabis sector for the last four years and has reported extensively, with a particular focus on patients and consumers. Under Sarah’s leadership, Cannabis Health won 'Best CBD Magazine' at the World CBD Awards 2022. She is now a regular contributor to Forbes, covering cannabis with a focus on Europe and has moderated panels at leading industry events, including Cannabis Europa, Product Earth and Drug Science’s UK Patient Conference, which she helped curate in November 2023. Beyond cannabis, Sarah also has experience reporting on women’s health, health technology, biotech, longevity and neurorehabilitation medicine. She has an NCTJ accreditation and graduated from her MA in Journalism at the University of Sunderland with a distinction. She has also completed specialist training through the Medical Cannabis Clinicians Society in the UK. Sarah is passionate about tackling stigma and misinformation with science, without losing sight of the importance of the patient experience. Through her journalism and content, she helps readers navigate complex topics in a way that resonates and aims to empower individuals to make informed decisions about their health and wellbeing, with accurate, evidence-based information.
With millions of people thought to be self-medicating with cannabis in the UK, websites like Dispenseree have become increasingly popular despite their illegality. But there are numerous risks when it comes to buying cannabis online, especially when it's for medicinal use.
An estimated 2.6 million people are living with ADHD in the UK and diagnoses are on the rise as general awareness of neurodivergent disorders grows. At the same time, many patients are reporting benefits from medical cannabis, with ADHD now one of the most common conditions for which it is prescribed.
If you’re able to obtain a prescription for medical cannabis in the UK, the chances are you’ll be prescribed it as an oil or as dried flower for vaping. But what’s the difference between these two delivery routes? How do they both work? And how do you know which one is right for you?
Releaf offers every patient a medical cannabis card with their prescription to help ensure peace of mind when administering their medicine in public. Here’s everything you need to know about how it works.
This article will take a deep dive into the global evidence base for the medicinal use of cannabis, with a specific focus on clinical trials and emerging areas of research in the UK. We’ll explore how the findings can inform modern healthcare and potentially make a real difference to millions of patients in the UK.
"Since starting my treatment plan with Releaf, I’m genuinely shocked at how well it has worked."Chloe Durrington, Releaf patient
